Dravet Syndrome, a rare genetic epilepsy that usually appears in infancy, may be sustained in part by the brain's own immune system, according to a preclinical study from Weill Cornell Medicine published July 29 in Nature Neuroscience. The researchers pinpointed an inflammatory pathway known as cGAS-STING-interferon (IFN-I) signaling as a major contributor to how the disease progresses.
Research on Dravet Syndrome has largely centered on how mutations in the SCN1A gene scramble electrical signaling between neurons. The Weill Cornell team describes something layered on top of that: DNA released from stressed neurons appears to trigger an immune response that then feeds itself, with inflammation helping to drive and maintain the disease rather than simply following it.
Dr. Li Gan, the study's senior author and director of the Helen and Robert Appel Alzheimer's Disease Research Institute at Weill Cornell Medicine, framed the result as connecting seizures to brain immunity in a way that had not been fully appreciated. That matters clinically because children with Dravet Syndrome often have seizures that resist medication, along with developmental, cognitive and behavioral difficulties - a profile that suggests current drugs, which target electrical activity, are missing part of the problem.
The practical hope is that interrupting the cGAS-STING-IFN-I pathway could open a different line of attack on epilepsy disorders. This work is preclinical, so the next step is establishing whether blocking that signaling changes the course of disease in ways that translate to patients.